Investor Overview

Corporate Profile

Investor Highlights

Corporate Profile

Read Now
Corporate Profile

Investor Presentation

Read Now
highlightbg1

Our Pipeline

Learn More
highlightbg2
  • Price
  • Change

  • Copyright West LLC.
    Minimum 15 minutes delayed.
Recent Releases

Recent Releases

June 18, 2019

BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

June 17, 2019

BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab

June 14, 2019

BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)

Key Metrics

Key Metrics

  • 2,400

    Employees

  • 800+

    Clinical team

  • 4

    Continents

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept